Full Year 2023 Investor Presentation
22
Investor presentation
Full year 2023
Novo Nordisk has leading positions in diabetes, obesity and
haemophilia
Novo NordiskⓇ
Diabetes care
DKK
billion
1200
1000
Obesity care
DKK
billion
Haemophilia
DKK
billion
#1
50%
80
88
40%
60
60
#1
120%
100
#3
50%
100%
80
40%
800
80%
30%
600
40
40
20%
400
20
CAGR¹ value: 16.6%
20
10%
200
60
30%
60%
40
40
20%
40%
CAGR² value: 120.5%
20
20%
20
10%
CAGR³ value: 5.9%
0
Nov
2018
Market value
0%
0
Nov
2023
Nov
2021
Market value
0%
0
Nov
2023
FY
2019
0%
FY
2022
Market value
NN value market share (RHS)
Global market position
NN value market share (RHS)
Global market position
-NN value market share (RHS)
Global market position
1CAGR for 5-year period; 2 CAGR for 2-year period; 3 CAGR for 3-year period; RHS: Right-hand side; Note: Annual sales figures for haemophilia A, B and bypassing agent segments, plasma derived products excluded except FeibaⓇ;
NN: Novo Nordisk
Source: Company reports for haemophilia market; IQVIA MAT, Nov 2023; Note: Market values are based on the list pricesView entire presentation